Pharmaco(epi)genomics in ovarian cancer

Area of Science:

• Oncology
• Pharmacogenomics
• Epigenetics

Background:

• Ovarian cancer exhibits significant variability in chemotherapy response, necessitating personalized medicine approaches.
• Genomic polymorphisms (e.g., ERCC1, ABCB1, p53) and epigenomic alterations (e.g., MLH1, BRCA1 methylation, microRNA regulation) influence drug response.

Purpose of the Study:

• To review the role of pharmacogenomic and pharmacoepigenomic biomarkers in ovarian cancer chemoresponse.
• To highlight the need for robust clinical trials and integrated approaches for biomarker validation.

Main Methods:

• Review of existing literature on genomic and epigenomic factors in ovarian cancer chemoresistance.
• Discussion of the importance of germ-line epigenetic changes and tumor-specific alterations.

Main Results:

• Pharmacogenomic and pharmacoepigenomic factors significantly impact ovarian cancer treatment efficacy.
• Current studies often focus on single loci, potentially oversimplifying complex biological interactions.

Conclusions:

• Validated pharmacogenomic and epigenomic biomarkers are crucial for advancing individualized ovarian cancer therapy.
• Integrated approaches analyzing genomic, epigenomic, and expression patterns are essential for future research and clinical application.